156 related articles for article (PubMed ID: 34181760)
1. Flexible use of copula-type model for dose-finding in drug combination clinical trials.
Hashizume K; Tshuchida J; Sozu T
Biometrics; 2022 Dec; 78(4):1651-1661. PubMed ID: 34181760
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the performance of copula models in phase I-II clinical trials under model misspecification.
Cunanan K; Koopmeiners JS
BMC Med Res Methodol; 2014 Apr; 14():51. PubMed ID: 24731155
[TBL] [Abstract][Full Text] [Related]
3. Competing designs for drug combination in phase I dose-finding clinical trials.
Riviere MK; Dubois F; Zohar S
Stat Med; 2015 Jan; 34(1):1-12. PubMed ID: 24464821
[TBL] [Abstract][Full Text] [Related]
4. A hybrid design for dose-finding oncology clinical trials.
Liao JJZ; Zhou F; Zhou H; Petruzzelli L; Hou K; Asatiani E
Int J Cancer; 2022 Nov; 151(9):1602-1610. PubMed ID: 35802470
[TBL] [Abstract][Full Text] [Related]
5. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
[TBL] [Abstract][Full Text] [Related]
6. Adaptive design for identifying maximum tolerated dose early to accelerate dose-finding trial.
Kojima M
BMC Med Res Methodol; 2022 Apr; 22(1):97. PubMed ID: 35382745
[TBL] [Abstract][Full Text] [Related]
7. A clinical phase I dose-finding design with adaptive shrinking boundaries for drug combination trials.
Li Z; Xu Z; Zhang A; Qi G; Li Z
BMC Med Res Methodol; 2023 Mar; 23(1):57. PubMed ID: 36864387
[TBL] [Abstract][Full Text] [Related]
8. Dose escalation with over-dose and under-dose controls in Phase I/II clinical trials.
Chen Z; Yuan Y; Li Z; Kutner M; Owonikoko T; Curran WJ; Khuri F; Kowalski J
Contemp Clin Trials; 2015 Jul; 43():133-41. PubMed ID: 26012358
[TBL] [Abstract][Full Text] [Related]
9. A comparison of model-free phase I dose escalation designs for dual-agent combination therapies.
Barnett H; George M; Skanji D; Saint-Hilary G; Jaki T; Mozgunov P
Stat Methods Med Res; 2024 Feb; 33(2):203-226. PubMed ID: 38263903
[TBL] [Abstract][Full Text] [Related]
10. Keyboard design for phase I drug-combination trials.
Pan H; Lin R; Zhou Y; Yuan Y
Contemp Clin Trials; 2020 May; 92():105972. PubMed ID: 32151751
[TBL] [Abstract][Full Text] [Related]
11. Local continual reassessment methods for dose finding and optimization in drug-combination trials.
Zhang J; Yan F; Wages NA; Lin R
Stat Methods Med Res; 2023 Oct; 32(10):2049-2063. PubMed ID: 37593951
[TBL] [Abstract][Full Text] [Related]
12. Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy.
Liu R; Lin J; Li P
Contemp Clin Trials; 2020 Sep; 96():106083. PubMed ID: 32659438
[TBL] [Abstract][Full Text] [Related]
13. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
Lin R; Yin G
Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
[TBL] [Abstract][Full Text] [Related]
14. Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering.
Guo B; Li Y
Stat Med; 2015 Feb; 34(5):859-75. PubMed ID: 25413162
[TBL] [Abstract][Full Text] [Related]
15. Dynamic ordering design for dose finding in drug-combination trials.
Zhang T; Yang Z; Yin G
Pharm Stat; 2021 Mar; 20(2):348-361. PubMed ID: 33236520
[TBL] [Abstract][Full Text] [Related]
16. Bayesian optimization design for finding a maximum tolerated dose combination in phase I clinical trials.
Takahashi A; Suzuki T
Int J Biostat; 2021 Apr; 18(1):39-56. PubMed ID: 33818029
[TBL] [Abstract][Full Text] [Related]
17. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.
Yin J; Paoletti X; Sargent DJ; Mandrekar SJ
Clin Trials; 2017 Dec; 14(6):611-620. PubMed ID: 28764555
[TBL] [Abstract][Full Text] [Related]
18. An adaptive gBOIN design with shrinkage boundaries for phase I dose-finding trials.
Mu R; Hu Z; Xu G; Pan H
BMC Med Res Methodol; 2021 Dec; 21(1):278. PubMed ID: 34895153
[TBL] [Abstract][Full Text] [Related]
19. A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials.
Zhang L; Yuan Y
Stat Med; 2016 Nov; 35(27):4924-4936. PubMed ID: 27580928
[TBL] [Abstract][Full Text] [Related]
20. A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials.
Tighiouart M; Li Q; Rogatko A
Stat Med; 2017 Jan; 36(2):280-290. PubMed ID: 27060889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
